Q-omics provides the consensus-scored C22orf15 profile across patient tissues and cancer cell-line models. C22orf15 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, C22orf15 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, C22orf15 RNA expression shows 15,640 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, THCA, and TGCT as cancer lineages where C22orf15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C22orf15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C22orf15 survival associations across molecular data types. C22orf15 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C22orf15 RNA expression–survival associations across cancer types. High C22orf15 expression shows unfavorable associations in ACC, LGG, KICH and THCA, but favorable associations in CESC and BLCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for C22orf15 RNA expression.
This table summarizes C22orf15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for C22orf15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C22orf15 shows lower tumor expression in THCA, LUAD, LUSC, COAD, BRCA and KIRC. The THCA box plot shows higher C22orf15 RNA expression in normal versus tumor tissue (log2 FC = −0.272, t-test p < 0.001).
This table shows molecular features associated with C22orf15 in patient tissues and cancer cell lines. In patient samples, C22orf15 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, C22orf15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
